MALCOLM BRENNER to Genetic Vectors
This is a "connection" page, showing publications MALCOLM BRENNER has written about Genetic Vectors.
Connection Strength
4.309
-
Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther. 2018 01 03; 26(1):1-2.
Score: 0.444
-
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506.
Score: 0.373
-
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther. 2009 Nov; 20(11):1229-39.
Score: 0.253
-
Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program. 2009; 675-81.
Score: 0.238
-
Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood. 2004 Oct 15; 104(8):2272-80.
Score: 0.173
-
Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
Score: 0.157
-
Response to "systemic adenovirus delivery". Mol Ther. 2002 Aug; 6(2):138.
Score: 0.153
-
Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther. 2002 Mar; 5(3):233-41.
Score: 0.148
-
Gene-marking studies of hematopoietic cells. Int J Hematol. 2001 Jan; 73(1):14-22.
Score: 0.137
-
Reports of adenovector "death" are greatly exaggerated. Mol Ther. 2000 Mar; 1(3):205.
Score: 0.129
-
Gene transfer by adenovectors. Blood. 1999 Dec 15; 94(12):3965-7.
Score: 0.127
-
IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998 Sep 15; 92(6):1941-9.
Score: 0.117
-
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res. 2018 01; 6(1):47-58.
Score: 0.110
-
A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood. 1997 Jan 01; 89(1):119-27.
Score: 0.104
-
An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. Mol Ther. 2015 Sep; 23(9):1475-85.
Score: 0.093
-
Immunomodulatory effects of human neuroblastoma cells transduced with a retroviral vector encoding interleukin-2. Cancer Gene Ther. 1994 Dec; 1(4):253-8.
Score: 0.090
-
Genetic marking and manipulation of hematopoietic progenitor cells using retroviral vectors. Immunomethods. 1994 Dec; 5(3):204-10.
Score: 0.090
-
The eyes have it. Mol Ther. 2010 Mar; 18(3):451-2.
Score: 0.065
-
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91.
Score: 0.063
-
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74.
Score: 0.058
-
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):913-24.
Score: 0.053
-
Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther. 2004 Dec; 15(12):1229-42.
Score: 0.045
-
Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 2004 Jul; 10(1):5-18.
Score: 0.044
-
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 2023 03 01; 31(3):801-809.
Score: 0.039
-
Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. Exp Hematol. 2001 Aug; 29(8):952-61.
Score: 0.036
-
Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001 Jun; 8(12):930-7.
Score: 0.035
-
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).
Score: 0.035
-
Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001 Apr 10; 12(6):659-70.
Score: 0.035
-
Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther. 2000 Aug; 7(8):1120-6.
Score: 0.033
-
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
Score: 0.031
-
"The end of the beginning": molecular and cellular biology of gene therapy keystone. 14-20 January 1999. Biochim Biophys Acta. 1999 Jul 29; 1424(1):R5-9.
Score: 0.031
-
Use of gene marking technologies in oncology. Forum (Genova). 1998 Oct-Dec; 8(4):342-53.
Score: 0.029
-
Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90.
Score: 0.028
-
EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8.
Score: 0.028
-
Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther. 1997 Nov 01; 8(16):1935-43.
Score: 0.027
-
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct 03; 21(1):17-26.
Score: 0.027
-
Emerging applications of gene transfer in the hematopoietic cancers. J Pediatr Hematol Oncol. 1997 Jan-Feb; 19(1):1-6.
Score: 0.026
-
Gene transfer in haematological malignancy. Ann Med. 1996 Dec; 28(6):491-7.
Score: 0.026
-
Gene marking. Hum Gene Ther. 1996 Oct 20; 7(16):1927-36.
Score: 0.026
-
Gene transfer and therapeutic drug monitoring. Ther Drug Monit. 1996 Aug; 18(4):322-7.
Score: 0.025
-
High-efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin-2 vectors. Hum Gene Ther. 1996 Jun 20; 7(10):1233-9.
Score: 0.025
-
Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation. Hum Gene Ther. 1996 Mar 20; 7(5):655-67.
Score: 0.025
-
Vectors in cancer therapy: how will they deliver? Cancer Gene Ther. 1995 Dec; 2(4):291-7.
Score: 0.024
-
Human somatic gene therapy: progress and problems. J Intern Med. 1995 Mar; 237(3):229-39.
Score: 0.023
-
Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 2014 Nov; 21(11):472-482.
Score: 0.022
-
Current status of gene transfer into haemopoietic progenitor cells: application to Langerhans cell histiocytosis. Br J Cancer Suppl. 1994 Sep; 23:S56-7.
Score: 0.022
-
Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. Hum Gene Ther. 1994 Apr; 5(4):481-99.
Score: 0.021
-
Gene marking to improve the outcome of autologous bone marrow transplantation. J Hematother. 1994; 3(1):33-6.
Score: 0.021
-
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
Score: 0.021
-
The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Ther. 2013 Sep; 20(9):958-62.
Score: 0.020
-
Gene transfer into human hematopoietic progenitor cells: a review of current clinical protocols. J Hematother. 1993; 2(1):7-17.
Score: 0.020
-
Molecular analysis of retroviral transduction in chronic myelogenous leukemia. Hum Gene Ther. 1991; 2(4):317-21.
Score: 0.017
-
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70.
Score: 0.016
-
Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. J Immunother. 2009 Jun; 32(5):524-38.
Score: 0.015
-
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402.
Score: 0.015
-
Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol Ther. 2008 Mar; 16(3):599-606.
Score: 0.014
-
Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences. Cytotherapy. 2008; 10(5):526-39.
Score: 0.014
-
Progress and prospects: gene therapy clinical trials (part 2). Gene Ther. 2007 Nov; 14(22):1555-63.
Score: 0.014
-
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802.
Score: 0.013
-
IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther. 2007 Oct; 14(10):819-27.
Score: 0.013
-
E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther. 2004 Sep; 11(9):585-93.
Score: 0.011
-
Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids. Mol Ther. 2004 Apr; 9(4):489-95.
Score: 0.011
-
A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther. 2004 Feb; 11(2):81-91.
Score: 0.011
-
Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood. 2004 Feb 01; 103(3):1011-9.
Score: 0.010
-
Selection of chronic lymphocytic leukemia binding peptides. Cancer Res. 2003 Sep 01; 63(17):5213-7.
Score: 0.010
-
Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther. 2003 Jun; 7(6):748-54.
Score: 0.010
-
Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther. 2003 Apr 10; 14(6):545-59.
Score: 0.010
-
Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy. 2003; 5(3):231-40.
Score: 0.010
-
Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer. 2001 Sep 01; 93(5):706-13.
Score: 0.009
-
Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther. 2000 Feb; 1(2):171-9.
Score: 0.008
-
Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease. J Clin Immunol. 2000 Jan; 20(1):1-9.
Score: 0.008
-
Transduction of CD34(+) and CD34(-)/lin(-) hemopoietic progenitors by lentivirus vectors. Cytotherapy. 1999; 1(6):433-8.
Score: 0.007
-
Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells. J Hematother. 1998 Jun; 7(3):217-24.
Score: 0.007
-
Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 1998 May 20; 9(8):1237-50.
Score: 0.007
-
Expression of the human immunodeficiency virus type 1 primer binding sequence inhibits HIV-1 replication. Hum Gene Ther. 1998 Mar 01; 9(4):587-90.
Score: 0.007
-
Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther. 1995 Sep; 6(9):1231-55.
Score: 0.006
-
Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
Score: 0.005
-
Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. Hum Gene Ther. 1992 Apr; 3(2):137-45.
Score: 0.005